Image

Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy

Tabelecleucel trial for transplant patients with EBV-related lymphoproliferative disease.

Recruiting
All
Phase 3
  • Simplified description (AI rewritten)
  • Technical description (Original)

This study explores using **tabelecleucel** to treat **Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD)**. EBV+ PTLD is a condition where certain white blood cells grow out of control after someone has had a transplant. The study focuses on people who have already tried **rituximab** (a medicine that targets specific cells) and possibly chemotherapy, but these treatments didn't work.

Tabelecleucel is given through an **intravenous (IV)** line, which means it goes directly into the bloodstream. It is administered in cycles of 5 weeks. Participants receive the treatment on Days 1, 8, and 15, and then doctors observe them for the rest of the cycle. The study lasts for a total of 5 years to check on the disease and survival.

  • Participants undergo 5-week treatment cycles with IV tabelecleucel.
  • The study includes a 5-year follow-up period.
  • Participants must have previously tried rituximab treatment.
Print
Study details
    Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD)
    Solid Organ Transplant Complications
    Lymphoproliferative Disorders
    Allogeneic Hematopoietic Cell Transplant
    Stem Cell Transplant Complications

NCT03394365

Atara Biotherapeutics

26 April 2025

Contact a study center
Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Race
Ethnicity
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.